3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
3
Phase 2
2
Phase NA
1
Status
Unknown
6
Recruiting
5
Completed
5
Not yet recruiting
2
Withdrawn
1
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Breast Neoplasms
120
Neoplasms
75
Prostatic Neoplasms
70
Lung Neoplasms
35
Carcinoma, Non-Small-Cell Lung
33
Pancreatic Neoplasms
32
Colorectal Neoplasms
30
Head and Neck Neoplasms
29
Carcinoma, Hepatocellular
24
Brain Neoplasms
24
Colonic Neoplasms
22
Motor Activity
19
Carcinoma, Renal Cell
17
Pain
16
Ovarian Neoplasms
16
Neoplasm Metastasis
14
Hematologic Neoplasms
14
Urinary Bladder Neoplasms
13
Rectal Neoplasms
13
Lymphoma, Follicular
13
Fatigue
13
Sarcoma
12
Precursor Cell Lymphoblastic Leukemia-Lymphoma
12
Glioblastoma
12
Lymphoma
11
Liver Neoplasms
11
Glioma
11
Squamous Cell Carcinoma of Head and Neck
10
Leukemia
10
Anxiety Disorders
10
Interventions
3-fluoro-2-(4-((2-nitro-1H-imidazol-1-yl)methyl)-1H-1,2,3-triazol-1-yl)propan-1-ol
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase NA
×
Withdrawn
×
Disease Progression
×
Clear all
NCT01210131
2013-08-27
HX4 in SCLC
Maastricht Radiation Oncology
Phase NA
Withdrawn